Comparative Pharmacology
Head-to-head clinical analysis: MITHRACIN versus MITOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MITHRACIN versus MITOSOL.
MITHRACIN vs MITOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to DNA and inhibits RNA synthesis; also inhibits osteoclast activity by blocking mRNA transcription.
Mitomycin C is an alkylating antibiotic that inhibits DNA synthesis by forming cross-links between complementary DNA strands, thereby blocking DNA replication and transcription.
25 mcg/kg intravenously over 4-6 hours daily for 8-10 days; for hypercalcemia, 25 mcg/kg intravenously once. Maximum cumulative dose due to toxicity: 10-30 mcg/kg per course.
0.04 mg/kg intravenously once weekly for 4 weeks, then every 3 weeks thereafter; maximum single dose 3.5 mg.
None Documented
None Documented
Terminal half-life: 18-36 hours (mean 27 hours); clinically, this supports intermittent dosing every 1-2 weeks to avoid accumulation.
Terminal: 3-6 hours; in renal impairment, extends to 10-20 hours
Renal: ~90% unchanged within 24 hours; biliary/fecal: <10% as metabolites.
Renal: 60% unchanged; biliary/fecal: 40% as metabolites
Category C
Category C
Antineoplastic Antibiotic
Antineoplastic Antibiotic